Siegel R, Naishadham D, Jemal A. Cancer statistics. 2012. CA Cancer J Clin. 2012;62:10–29.
Article
PubMed
Google Scholar
Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. A Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372–9.
Article
CAS
PubMed
Google Scholar
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
Article
CAS
PubMed
Google Scholar
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
Article
CAS
PubMed
Google Scholar
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.
Article
CAS
PubMed Central
PubMed
Google Scholar
Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol. 2013;24:66–82.
Article
CAS
PubMed Central
PubMed
Google Scholar
Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014;25:249–59.
Article
CAS
PubMed Central
PubMed
Google Scholar
Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010;277:3890–903.
Article
CAS
PubMed
Google Scholar
Roy M, Marchetti D. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem. 2009;106:200–9.
Article
CAS
PubMed Central
PubMed
Google Scholar
Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood. 2010;115:2449–57.
Article
CAS
PubMed Central
PubMed
Google Scholar
Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer. 2006;118:1609–17.
Article
CAS
PubMed
Google Scholar
Ginath S, Menczer J, Friedmann Y, Aingorn H, Aviv A, Tajima K, et al. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. Int J Oncol. 2001;18:1133–44.
CAS
PubMed
Google Scholar
Kodama J, Shinyo Y, Hashen G, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase messenger RNA expression in epithelial ovarian tumor. Int J Mol Med. 2003;12:961–4.
CAS
PubMed
Google Scholar
Zeng C, Ke ZF, Luo WR, Yao YH, Hu XR, Jie W, et al. Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo. Med Oncol. 2013;30:403.
Article
PubMed
Google Scholar
Davidson B, Shafat I, Risberg B, Ilan N, Trope’ CG, Vlodavsky I, et al. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol. 2007;104:311–9.
Article
CAS
PubMed
Google Scholar
Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol. 2003;14:1505–10.
Article
CAS
PubMed
Google Scholar
Zhang W, Yang HC, Wang Q, Yang ZJ, Chen H, Wang SM, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011;31:3423–8.
CAS
PubMed
Google Scholar
Basappa J, Murugan S, Kavitha CV, Purushothaman A, Nevin KG, Sugahara K, et al. A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-alpha. Cancer Lett. 2010;297:231–43.
Article
CAS
PubMed
Google Scholar
Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs. 2008;17:1769–76.
Article
CAS
PubMed
Google Scholar
Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010;21:1302–7.
Article
CAS
PubMed
Google Scholar
Taylor CW, Lui R, Fanta P, Salmon SE. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst. 1992;84:489–94.
Article
CAS
PubMed
Google Scholar
Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, et al. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;66:1019–29.
Article
CAS
PubMed Central
PubMed
Google Scholar
Hutson PR, Tutsch KD, Rago R, Arzoomanian R, Alberti D, Pomplun M, et al. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin Cancer Res. 1998;4:1429–36.
CAS
PubMed
Google Scholar
Larsen AK. Suramin: an anticancer drug with unique biological effects. Cancer Chemother Pharmacol. 1993;32:96–8.
Article
CAS
PubMed
Google Scholar
Nakajima M, De Chavigny A, Johnson CE, Hamada J, Stein CA, Nicolson GL. Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem. 1991;266:9661–6.
CAS
PubMed
Google Scholar
Firsching A, Nickel P, Mora P, Allolio B. Antiproliferative and angiostatic activity of suramin analogues. Cancer Res. 1995;55:4957–61.
CAS
PubMed
Google Scholar
Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growthand metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999;59:3433–41.
CAS
PubMed
Google Scholar
Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer. 2003;104:167–74.
Article
CAS
PubMed
Google Scholar
Sadashiva MP, Basappa S, Nanjundaswamy S, Li F, Manu KA, Sengottuvelan M, et al. Anti-cancer activity of novel dibenzo[b, f]azepine tethered isoxazoline derivatives. BMC Chem Biol. 2012;12:5.
Article
PubMed Central
PubMed
Google Scholar
Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin’s development: what did we learn? Invest New Drugs. 2002;20:209–19.
Article
CAS
PubMed
Google Scholar
Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE. Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer. 1992;28A:864–6.
Article
CAS
PubMed
Google Scholar
Kikuchi Y, Hirata J, Hisano A, Tode T, Kita T, Nagata I. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). Gynecol Oncol. 1995;58:11–5.
Article
CAS
PubMed
Google Scholar
La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, et al. Suramin-induced polyneuropathy. Neurology. 1990;40:954–60.
Article
PubMed
Google Scholar
Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ. Mineralocorticoid insufficiency due to suramin therapy. Cancer. 1996;78:2411–20.
Article
CAS
PubMed
Google Scholar
Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, et al. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer. 1994;74:1612–4.
Article
CAS
PubMed
Google Scholar
Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A. 2000;97:8658–63.
Article
CAS
PubMed Central
PubMed
Google Scholar
Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2006;24(27):4384–90.
Article
CAS
PubMed
Google Scholar
Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, et al. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012;70:49–56.
Article
CAS
PubMed Central
PubMed
Google Scholar
Horiuchi KY, Eason MM, Ferry JJ, Planck JL, Walsh CP, Smith RF, et al. Assay development for histone methyltransferases. Assay Drug Dev Technol. 2013;11:227–36.
Article
CAS
PubMed Central
PubMed
Google Scholar
Botta G, De Santis LP, Saladino R. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins. Curr Med Chem. 2012;19:5871–84.
Article
CAS
PubMed
Google Scholar
Iglesias RM, Spray DC. Pannexin1-mediated ATP release provides signal transmission between Neuro2A cells. Neurochem Res. 2012;37:1355–63.
Article
CAS
PubMed Central
PubMed
Google Scholar
Singh PK, Chan PF, Hibbs MJ, Vazquez MJ, Segura DC, Thomas DA, et al. High-yield production and characterization of biologically active GST-tagged human topoisomerase IIα protein in insect cells for the development of a high-throughput assay. Protein Expr Purif. 2011;76:165–72.
Article
CAS
PubMed
Google Scholar
Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Garcia S, et al. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing. Am J Obstet Gynecol. 2007;197:359. e1-6.
Article
PubMed
Google Scholar
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
Article
CAS
PubMed
Google Scholar
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22.
Article
CAS
PubMed
Google Scholar
Hirshoren N, Bulvik R, Neuman T, Rubinstein AM, Meirovitz A, Elkin M. Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med. 2014;18:181–6.
Article
CAS
PubMed Central
PubMed
Google Scholar
Wang H, Mo P, Ren S, Yan C. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. J Biol Chem. 2010;285:13201–10.
Article
CAS
PubMed Central
PubMed
Google Scholar
Kang KF, Wang XW, Chen XW, Kang ZJ, Zhang X, Wilbur RR, et al. Beclin 1 and nuclear factor-κBp65 are upregulated in hepatocellular carcinoma. Oncol Lett. 2013;5:1813–8.
PubMed Central
PubMed
Google Scholar
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.
Article
CAS
PubMed
Google Scholar